# Theranostic Implication of Complementary Medicines Against Interleukin Receptors and Gp-130 Proteins

> **NCT04690920** · NA · COMPLETED · sponsor: **University of Lahore** · enrollment: 200 (actual)

## Conditions studied

- Corona Virus Disease 2019 (COVID-19)

## Interventions

- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT04690920
- **Lead sponsor:** University of Lahore
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-23
- **Primary completion:** 2020-12-10
- **Final completion:** 2020-12-10
- **Target enrollment:** 200 (ACTUAL)
- **Last updated:** 2020-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04690920

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04690920, "Theranostic Implication of Complementary Medicines Against Interleukin Receptors and Gp-130 Proteins". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04690920. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*